
What to know about GLP-1 supplements for weight loss
From colorful patches and fruit punch-flavored gummies to prebiotic powders and under-the-tongue tinctures, dietary supplements that claim to 'complement' or 'supercharge' the body's levels of the gut hormone GLP-1 are a dime a dozen. While compounded drugs require at least a virtual consultation with a clinician to get a prescription, supplements are available over the counter.
At best, such products are misleading, said Jamie Alan, an associate professor of pharmacology and toxicology at Michigan State University's College of Human Medicine. So-called GLP-1 supplements, named to echo the class of glucagon-like peptide-1 agonist drugs that includes Wegovy and Zepbound, are likely to be ineffective for weight loss.
'If you can buy it without a prescription, it's not an actual GLP-1 drug,' Alan said. 'It is something else that's marketed to support your endogenous GLP-1 production. These things are just older weight loss [supplements] that are rebranded, and there's really no scientific evidence for these.'
Ashwagandha and green tea extract are among the natural ingredients that have been recycled in diet products for decades, Alan said. Ashwagandha is often advertised as a stress reliever, and though the stress hormone cortisol is tied to weight gain, there's little proof the evergreen shrub directly helps shed pounds. Green tea and green tea extract may have a 'possible modest effect on body weight,' according to mixed research cited by the Office of Dietary Supplements, some of which links the extract to liver damage.
'We're coming back to these products that have been ineffective in the past,' Alan said. Ingredients popping up on GLP-1 supplement labels include everything from berberine to chromium to saffron extract, which have a minimal body of research supporting their effects on weight loss.
What's missing from the ingredient lists is also of note.
The brand Kind Patches indicates its GLP-1 adhesive 'does not contain synthetic GLP-1 and is not a GLP-1 agonist drug.' Lemme, Kourtney Kardashian Barker's wellness brand, features an identical disclaimer for its GLP-1 Daily Support Capsules. Trim Biome GLP-1, manufactured by Inno Supps, boasts 'clinically studied ingredients' but not the hormone in the product's name.
Lemme declined to comment; Inno Supps and Kind Patches didn't respond to a request for comment.
Jeff Ventura, the vice president of communications for the Council for Responsible Nutrition, a trade group for the supplement industry, said in a statement that there are 'no direct comparators' for GLP-1 drugs in the dietary supplement industry.
'While some supplement ingredients have shown promise in limited studies related to metabolic health and weight management, they do not have the same effects as GLP-1 drugs,' Ventura said.
'It is very tricky, because they'll put that big 'GLP-1' on there and it makes you think, 'Well, maybe this is the drug,' if you're not thinking about how to read these labels or if you don't know how to read these labels,' Alan said.
The FDA doesn't regulate dietary supplements for safety or effectiveness before they hit the market, whether they're a daily multivitamin or a post-workout protein powder. For that reason, the agency advises consulting a health care provider before adding any supplement to your regimen.
'There could be harm in some of these,' Alan said. 'There are going to be some people who might have a significant drug interaction, who might have a significant medical condition. In most people there's probably minimal risk of harm, but that's not true for everyone.'
Why are compounded GLP-1 drugs going away?
GLP-1 drugs aren't new, having been used to treat Type 2 diabetes since 2005. Demand soared after the FDA approved Wegovy and Zepbound for weight loss in 2021 and 2023, respectively. The ensuing shortages made it legal for compounding pharmacies to step in.
Compounding pharmacies typically mix, alter or combine drug ingredients to meet a patient's specific needs. For example, a pharmacy may make a liquid version of a drug that only comes in pill form for a patient who has trouble swallowing. During drug shortages, they're also authorized to craft medications that are 'essentially copies' of commercially available drugs.
Compounded versions of Wegovy and Zepbound skyrocketed in popularity — in part because they were generally sold for far less than their brand-name counterparts. Wegovy, for instance, has a list price of $1,349.02 for a four-week supply, though some insurance plans cover it. Meanwhile, WeightWatchers offers compounded semaglutide starting at $129 a month.
That's coming to an end: The FDA declared the tirzepatide shortage over in December and did the same for the semaglutide shortage in February. Compounders must now pull their products. The grace period for tirzepatide manufacturers is over, and semaglutide producers have until Tuesday or May 22, depending on whether they're a state-licensed pharmacy or an outsourcing facility.
That leaves a huge opening for GLP-1 supplement sellers to flood the $49.3 billion global market — and convince consumers a $15 pack of unproven patches will yield the same results as brand-name drugs that have undergone comprehensive clinical trials, said Dr. W. Scott Butsch, director of obesity medicine at the Cleveland Clinic Bariatric and Metabolic Institute.
Butsch, who has previously consulted for Novo Nordisk (maker of Wegovy) and Eli Lilly (maker of Zepbound), said he was already concerned about the ubiquity of compounded semaglutide and tirzepatide in recent years.
'The FDA states very clearly: These compounded versions are not the same,' he said. 'They don't have the same ingredients. They have not been tested.'
Worse still, Butsch said, compounders and now supplement companies are using lower pricing to target an already vulnerable clientele. Walmart, for example, sells a variety of GLP-1 supplements under $50.
Blair Cromwell, the director of global communications for Walmart's U.S. Marketplace, said in a statement that dietary supplements are sold by third-party sellers on its Marketplace.
'Our policy allows the sale of dietary supplements if they comply with applicable regulations as well as federal, state and local laws, and FTC guidelines,' Cromwell said, adding that the company would be likely to review products marketed as GLP-1 supplements and 'remove them if found to make inappropriate or inaccurate claims.'
'[The wellness market] has continued to prey on the desperate, and these are people who have poor access,' Butsch said. 'Patients with obesity have always had poor access to obesity medications.'
He added, 'You have some optimism among people who think that they can save some money and still get the benefit. But it's a bigger carrot that they're carrying in front of the horse now.'
'No simple dietary fix' can match GLP-1 results
Dr. Dariush Mozaffarian, a cardiologist and the director of Tufts University's Food Is Medicine Institute, said, 'There's no simple dietary fix that's going to do what these drugs do in a short amount of time.'
Still, the metabolic mechanism the supplements claim to achieve — boosting natural GLP-1 production — isn't without merit.
'The food I'm eating is biologic information that's activating hormones in my body, including GLP-1,' Mozaffarian said, noting that healthy fats and high-fiber foods have been shown to trigger GLP-1 production. But its natural release into the bloodstream is fleeting; GLP-1 drugs work by mimicking the hormone and keeping it around longer, which can aid in appetite suppression.
'It's too early for [GLP-1 supplements] to have science behind them,' Mozaffarian said. 'But I do think in the future we will be able to give people more clear recommendations on what's a natural, lifestyle way to boost your GLP-1 function.'
For now, he said, 'I wouldn't spend money on these supplements, I would spend money on healthy food.'
Alan, of Michigan State University, was blunt.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

South Wales Argus
2 hours ago
- South Wales Argus
Mounjaro prices double as weight loss jab popularity soars
US-based Eli Lilly says a 5mg dose will nearly double from £92 to £180 from September 1, while a 15mg pen will rise from £122 to £330. A Lilly spokesperson said: 'Following a review, Lilly will increase the UK list price for Mounjaro (tirzepatide) from 1 September to address pricing inconsistencies compared to other developed countries, including in Europe. We have reached an agreement with the NHS to ensure continued supply and patient access." The statement continues: 'While Lilly does not determine the prices that private healthcare providers set, we are working with them to maintain patient access. The UK was one of the first countries where Lilly launched Mounjaro, and our priority was to bring it to patients as quickly as possible during a time of limited supply of GLP-1 RA treatments for type 2 diabetes. 'At launch, Lilly agreed to a UK list price that is significantly below the European average to prevent delays in NHS availability." More than 1.5 million people in the UK are believed to be using weight-loss medication each month, with most buying the jabs from private pharmacies. Mounjaro users report surprising side effect - pharmacists share their tips — Bucks Free Press (@bucksfreepress) August 8, 2025 This comes as the Government has joined forces with Eli Lilly in a bid to tackle obesity. The move could see patients accessing care at pharmacies or by using online platforms. The £85 million programme from Eli Lilly and the Department for Science, Innovation and Technology (DSIT) has been designed to look at how obese patients can access weight management care more easily. This includes through community services, in pharmacies and online. Using these tools, eligible patients could be treated 'in a matter of months', according to Health Secretary Wes Streeting. Under the agreement, the Government will contribute up to £50 million in UK-wide investment. Meanwhile, Eli Lilly will back the programme with £35 million, and NHS organisations will be able to apply for a share of the funding. Recommended reading: Mounjaro warning as pens ruined by heatwave temperatures This comes as users are risking having to throw away perfectly good Mounjaro pens as they have overheated in the recent heatwave. Improper storage of Ozempic, Wegovy and Mounjaro during a heatwave could destroy the active ingredient in these jabs, potentially wiping out their effects entirely, even if the medication looks completely normal. 'We recommend treating your weight-loss pen the same way you'd treat insulin or any critical medication,' says Danielle Brightman, Clinical Director at Numan. 'When in doubt, don't risk it. Speak to a healthcare professional and arrange a replacement.' 8 tips to protect Mounjaro and other weight-loss injections during hot weather Use a medical-grade cool bag. Transport your pen in a proper, insulated container designed for sensitive medications. Don't use improvised ice packs that might freeze the pen by accident. Never leave your pen in hot places. Even 10 minutes in a parked car or on a sunny kitchen counter could expose it to damaging heat if out of its delivery packaging or unrefrigerated. Always check the environment before setting it down. Store below 30°C once in use. Once opened and if not refrigerated, keep your pen in a shaded, ventilated area, away from heat sources, windows, and radiators. If you live in a flat or home without air conditioning, keep the pen in a bedroom or hallway that doesn't heat up from direct sun. Avoid storing near exterior walls if the property retains heat. Follow the usage timeline carefully. The storage instructions between medications. Wegovy after first use can last 6 weeks below 30 degrees then needs to be disposed of, whereas Mounjaro has a shorter time of 30 days below 30 degrees before needing to be disposed of. Stick to that timeframe, and if you're unsure whether it's still safe, consult your provider. Use a fridge thermometer at home. Fridge temperatures can fluctuate, especially in older models or over-packed shelves. A simple digital fridge thermometer can help ensure your pen is always stored between 2–8°C before first use. Planning to travel? Use airline-friendly cooling cases. If you're flying or taking long journeys, consider TSA-approved insulated medication pouches with cooling gel packs. Always store the pen in carry-on luggage, not checked baggage, as cargo holds can get hot or cold. Set storage reminders on your phone. If you're prone to forgetting where you left your pen, set daily reminders to check if it's stored properly, especially during heatwaves or while travelling. Don't store near appliances or steam sources. Keep pens away from kettles, toasters, ovens, dishwashers, and anywhere that might experience sudden heat or humidity, especially in small kitchens or shared spaces. Injections like Ozempic, Wegovy, and Mounjaro are now widely used across the UK for appetite control and sustainable weight management. But despite their growing popularity and increasing availability now through the NHS, most patients don't realise the strict temperature guidelines that must be followed to keep these drugs effective. 'We speak to patients every day who are using GLP-1s for the first time,' says Danielle. 'With temperatures set to soar again this summer, it's crucial we raise awareness about safe medication storage. Heat damage isn't always obvious, but it can have a huge impact on effectiveness and safety."


The Independent
2 hours ago
- The Independent
You can now give yourself an at-home flu vaccine
For the first time, Americans can get their seasonal flu vaccine at home. Starting Friday, eligible adults in 34 states can order the FluMist Home - a nasal spray - online ahead of the upcoming flu season, European drugmaker AstraZeneca announced, calling it a 'transformational moment in the evolution of influenza protection.' FluMist was previously only available at pharmacies or doctors' offices. Now, interested people can go to to order the sprays, potentially saving time spent at a clinic or drug store. Once received, the vaccine should be stored in the refrigerator until it is used. Then, people between the ages of 18 and 49 years old can self-administer the vaccine. FluMist Home can be given to children and teens between the ages of two and 17 years old. A full dose is one spray in each nostril. FluMist may not prevent infection in everyone who takes it, but it works similarly to vaccines for measles and chickenpox. It contains weakened versions of viruses that trigger the immune system in the nose and throat, teaching it to build up immunity without causing infection. In rare cases, FluMist may cause serious side effects, including allergic reactions. But the most common side effects are a runny or stuffy nose, a sore throat and a fever of over 100 degrees. Some people should not take FluMist, including those with severe allergies to eggs, the vaccine's ingredients, or other flu vaccines, and kids who take aspirin or medicines containing aspirin. Children should also not take aspirin for four weeks after they get FluMist, unless told to do so by a healthcare provider. The spray, which was initially approved by the Food and Drug Administration in 2003 and was approved for at-home use without a healthcare professional last September, should be free for people with insurance, though there is an $8.99 shipping and processing fee. AstraZeneca said it hopes that all of the lower 48 states will have access to the spray in future flu seasons, although when that may be is unclear. The announcement comes on the heels of the worst flu season in 15 years, fueled by a cold winter, the spread of H5N1 bird flu, Covid, and other respiratory illnesses, and declining vaccine rates. Falling vaccination was 'a major cause of the surge,' Dr. Elizabeth Mack, the head of the pediatric critical care unit at the Medical University of South Carolina's Children's Health, told National Geographic. 'As influenza vaccination rates decline, especially among younger populations, this first-of-its-kind, at-home, needle-free option offers a critical opportunity to help make protection more accessible, convenient, and better aligned with the realities and current preferences of people's lives,' Dr. Ravi Jhaveri, the division head of infectious diseases at Northwestern University School of Medicine, said of FluMist Home, in a statement shared by AstraZeneca.


Daily Mail
4 hours ago
- Daily Mail
I have Ozempic vulva. It's the latest bizarre side effect of the miracle jabs no one talks about - and there's one treatment that can fix it
It's a miracle drug that has revolutionised weight loss for millions. But now some women are reporting that taking GLP-1 injections, more commonly known by brand names like Ozempic and Mounjaro, has produced an unsightly and uncomfortable side effect.